RxDoctor Payments Data

Ehsan Hadi, MD

Neurology · Carmichael, CANPI 1770684326

Payments from drug & device makers

$45,039in general payments, 2019–2025

Across 51 payments — averaging $883.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$26K
  • Acorda Therapeutics, Inc$10K
  • Amneal Pharmaceuticals LLC$3K
  • MDD US Operations, LLC$2K
  • Boston Scientific$1K
  • Merz Pharmaceuticals, LLC$1K
  • plus $2K from 6 others
$27,000in research payments, 2019–2025

Across 6 payments — averaging $4500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Acadia Pharmaceuticals Inc$27K

What the payments were for

  • Consulting fees$2,77514%
  • Speaking & faculty fees$14,24570%
  • Travel & lodging$1,4887%
  • Food & beverage$1,5398%
  • Education$1921%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,039 in reported general payments places this provider in the 85th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$491,709
Medicare patients
634
Services billed
49,882

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa135$278,816
AustedoDeutetrabenazine24$169,755
InbrijaLevodopa14$86,609
IngrezzaValbenazine Tosylate11$82,197
NourianzIstradefylline29$70,056
Carbidopa-LevodopaCarbidopa/Levodopa1,436$67,605
Rasagiline Mesylate188$54,203
GocovriAmantadine Hcl18$45,717
OngentysOpicapone24$27,229
Entacapone115$23,962
AmantadineAmantadine Hcl284$16,753
LinzessLinaclotide12$12,662
Primidone355$12,228
Propranolol Hcl295$7,804
Droxidopa15$7,107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$3,073$278,816135 claims
Teva Pharmaceuticals USA, Inc.Austedo$192$169,75524 claims
Acorda Therapeutics, IncInbrija$9,645$86,60914 claims
MDD US Operations, LLCGocovri$2,137$45,71718 claims
AbbVieLinzess$704$12,66212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,996 neurology providers in California.

Other neurology in Carmichael

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →